<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>115(9)</volume><submitter>Chiorean EG</submitter><journal>British journal of cancer</journal><pagination>e13</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5117797</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.</pubmed_title><pmcid>PMC5117797</pmcid><pubmed_authors>Liu H</pubmed_authors><pubmed_authors>Harris M</pubmed_authors><pubmed_authors>Whorf R</pubmed_authors><pubmed_authors>Manax V</pubmed_authors><pubmed_authors>Tabernero J</pubmed_authors><pubmed_authors>El-Maraghi R</pubmed_authors><pubmed_authors>Wee Ma W</pubmed_authors><pubmed_authors>Reni M</pubmed_authors><pubmed_authors>Romano A</pubmed_authors><pubmed_authors>Lu B</pubmed_authors><pubmed_authors>Goldstein D</pubmed_authors><pubmed_authors>Chiorean EG</pubmed_authors><pubmed_authors>Von Hoff DD</pubmed_authors><pubmed_authors>Shiansong Li J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.</name><description/><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Oct</publication><modification>2025-04-21T19:17:03.182Z</modification><creation>2025-04-05T17:33:16.284Z</creation></dates><accession>S-EPMC5117797</accession><cross_references><pubmed>27657342</pubmed><doi>10.1038/bjc.2016.306</doi></cross_references></HashMap>